Director Jens Holstein sells 5,000 shares of Veracyte Inc (VCYT)

On August 7, 2024, Jens Holstein, Director at Veracyte Inc (NASDAQ:VCYT), completed a sale of 5,000 shares of the company’s stock. The transaction was reported through an SEC filing on the same day. Following this sale, the insider now directly owns 27,878 shares of Veracyte Inc.

Veracyte Inc specializes in genomic diagnostics and is known for its advanced tests that help diagnose thyroid cancer, lung cancer and other diseases. The company’s tools aim to reduce unnecessary surgeries and enable precise diagnosis at the early stages of assessment.

Over the past year, Jens Holstein has sold a total of 10,000 shares and has not purchased any shares of the company. This latest transaction is part of a broader trend seen at Veracyte Inc., where there have been no insider purchases over the past year, but 10 insider sales.

Veracyte Inc. shares were trading at $29 on the day of the transaction. This price gives the company a market capitalization of approximately $2.25 billion. According to GF Value, the intrinsic value of the stock is estimated at $30.65, which suggests that the stock is fairly valued at a Price to GF Value ratio of 0.95.

The GF value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio and price-free cash flow and adjusted by a GuruFocus factor based on past earnings and growth as well as analysts’ estimates of future business development.

This insider sale may be of interest to current and prospective investors, as insider transactions can provide insight into the company’s management’s view of the stock’s value and future prospects.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.